• Aliases: R1507, RO4858696; RV001
    • Fully human IgG1 type monoclonal antibody directed against IGF-1R resulting in the activation of PI3K/AKT signal transduction and the prevention of binding of natural ligand IGF-1.
    • Currently no active clinical trials in the United States; has shown efficacy in Ewing sarcoma during phase 2 trials
    • Recommended phase 2 dose: 9 mg/kg weekly
    • Half-life: 8 to 10 days
    • Common side effects: Fatigue, anorexia
    (Kurzrock et al., 2010)
    Other topics in Targeted and Immunotherapy Agents